Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Vaidehi, Dave"'
Autor:
Dasha Shamarina, Martina Sluga-O’Callaghan, George Kassianos, Alen Marijam, Vaidehi Dave, Eric Davenport, Anar Andani, Desmond Curran, Pavitra Dewda, Robert Steffen
Publikováno v:
Vaccines, Vol 11, Iss 11, p 1645 (2023)
Despite the occurrence of several hepatitis A (hepA) and hepatitis B (hepB) outbreaks in Europe in the last few decades, not all European countries have implemented hepA and hepB vaccinations in their national immunization programs, especially for ad
Externí odkaz:
https://doaj.org/article/9739304f4aa94cbcaa1df620f3697058
Autor:
Richard W. Joseph, Frank Xiaoqing Liu, Qing Harshaw, Todd L. Saretsky, Alan S. Pickard, Scott J. Diede, Cynthia Macahilig, Alicia C. Shillington, Vaidehi Dave
Publikováno v:
Quality of Life Research
Background Pembrolizumab (PEMBRO) and ipilimumab + nivolumab (IPI + NIVO) are approved advanced melanoma (AM) immunotherapies. To address limited health-related quality of life (QoL) real-world evidence with immunotherapies in AM, we compared QoL in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::119e9bb144a339d1f772cb604809ecf6
https://doi.org/10.1007/s11136-020-02520-7
https://doi.org/10.1007/s11136-020-02520-7
Autor:
Petros Grivas, Pedro C. Barata, Helen Moon, Thomas E. Hutson, Shilpa Gupta, Cora N. Sternberg, Vaidehi Dave, Chad Downey, Alicia C. Shillington, Geeta Devgan, Melissa Kirker, Sheena Thakkar, Howard M. Katzenstein, Abhijeet Bhanegaonkar, Frank Liu, Jason Brown, Guru P. Sonpavde
Publikováno v:
Journal of Clinical Oncology. 41:465-465
465 Background: The JAVELIN Bladder 100 clinical trial demonstrated a significant overall survival and progression-free survival benefit with avelumab 1LM + best supportive care (BSC) vs BSC alone for la/mUC not progressing on platinum-based chemothe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45eb064bdbcf035c7c6ed0b282dd6d35
https://doi.org/10.1200/jco.2023.41.6_suppl.465
https://doi.org/10.1200/jco.2023.41.6_suppl.465
Autor:
Dhruvi, Shah, Naveen, Challagundla, Vaidehi, Dave, Ashok, Patidar, Bhaskar, Saha, Manish, Nivsarkar, Varsha B, Trivedi, Reena, Agrawal-Rajput
Publikováno v:
Phytomedicine. 99:153904
Berberine is a plant-derived alkaloid with potent anti-cancer activities. Berberine may redirect the tumor-promoting immunosuppressive M2 macrophages, to tumoricidal activated M1 macrophages. But such an anti-tumor function remains to be demonstrated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c07a340a69f99fafceb7f2730196598
https://doi.org/10.1016/j.phymed.2021.153904
https://doi.org/10.1016/j.phymed.2021.153904
Autor:
Petros Grivas, Pedro C. Barata, Helen Moon, Thomas E. Hutson, Shilpa Gupta, Cora N. Sternberg, A. Simon Pickard, Vaidehi Dave, Natalia Han, Alicia C. Shillington, Geeta Devgan, Ruth Kim, Sheena Thakkar, Howard Katzenstein, Abhijeet Bhanegaonkar, Frank Liu, Guru P. Sonpavde
Publikováno v:
Journal of Clinical Oncology. 40:TPS578-TPS578
TPS578 Background: The randomized phase 3 JAVELIN Bladder 100 trial demonstrated overall and progression-free survival (OS and PFS) benefit with Ave 1LM for la/mUC not progressed with platinum-containing chemotherapy (PCT). PATRIOT II aims to underst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2dd0502ad654f5e8b0abedd765a105c3
https://doi.org/10.1200/jco.2022.40.6_suppl.tps578
https://doi.org/10.1200/jco.2022.40.6_suppl.tps578
Autor:
Todd A. Lee, Frank Xiaoqing Liu, Alicia C. Shillington, Emilie Scherrer, Vaidehi Dave, Scott J. Diede, Richard W. Joseph, Qing Harshaw, Cynthia Macahilig
Publikováno v:
Journal of medical economics. 23(2)
Background: Both pembrolizumab (PEMBRO) and ipilimumab + nivolumab (IPI + NIVO) are FDA-approved immunotherapy regimens for advanced melanoma (AM). Each regimen has different toxicity profiles pote...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea03f3e3d324c5e59f46dbc80ab03ca2
https://pubmed.ncbi.nlm.nih.gov/31750751
https://pubmed.ncbi.nlm.nih.gov/31750751
Autor:
Alicia C. Shillington, Scott J. Diede, Vaidehi Dave, Qing Harshaw, Richard W. Joseph, Cynthia Macahilig, Frank Xiaoqing Liu
Publikováno v:
Immunotherapy. 10(16)
Aim: To explore factors associated with pembrolizumab (PEMBRO) versus ipilimumab + nivolumab (IPI+NIVO) selection in advanced melanoma. Materials & methods: Total of 12 academic and satellite clinics contributed to this study. Descriptive and logisti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a8146eefa0e5213b51401b0c59d7181
https://pubmed.ncbi.nlm.nih.gov/30407098
https://pubmed.ncbi.nlm.nih.gov/30407098
Autor:
Todd A. Lee, Cynthia Macahilig, Scott J. Diede, Emilie Taymor, Alicia C. Shillington, Vaidehi Dave, Frank Xiaoqing Liu, Qing Harshaw, Richard W. Joseph
Publikováno v:
Journal of Clinical Oncology. 37:9532-9532
9532 Background: Both pembrolizumab (PEMBRO) and combination ipilimumab + nivolumab (IPI+NIVO) are FDA-approved immunotherapies for advanced melanoma (AM). These two treatment regimens have different toxicity profiles which may impact health care res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a988dd66462c219824c111b86550b1a
https://doi.org/10.1200/jco.2019.37.15_suppl.9532
https://doi.org/10.1200/jco.2019.37.15_suppl.9532
Autor:
Todd L. Saretsky, Richard W. Joseph, Alicia C. Shillington, Vaidehi Dave, Alan S Pickard, Cynthia Macahilig, Scott J. Diede, Qing Harshaw, Frank Xiaoqing Liu
Publikováno v:
Journal of Clinical Oncology. 37:e21004-e21004
e21004 Background: Pembrolizumab (PEMBRO) and combination ipilimumab + nivolumab (IPI+NIVO) are FDA-approved immunotherapies for advanced melanoma (AM). HRQoL was better maintained with PEMBRO vs IPI in KEYNOTE-006. CheckMate-067 reported no clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bc234d0b6eb8dff51cab2ad6153d4c6
https://doi.org/10.1200/jco.2019.37.15_suppl.e21004
https://doi.org/10.1200/jco.2019.37.15_suppl.e21004
Autor:
Scott J. Diede, Qing Harshaw, Alicia C. Shillington, Vaidehi Dave, Frank Xiaoqing Liu, Cynthia Macahilig, Richard W. Joseph
Publikováno v:
Journal of Clinical Oncology. 36:9571-9571
9571Background: Both pembrolizumab (PEMBRO) and the combination of ipilimumab and nivolumab (IPI+NIVO) are approved by the US FDA for treatment of advanced (unresectable or metastatic) melanoma. Cl...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bddf6dd28af950c86bf12108ba9fe86
https://doi.org/10.1200/jco.2018.36.15_suppl.9571
https://doi.org/10.1200/jco.2018.36.15_suppl.9571